{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:41:41Z","timestamp":1781599301158,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10549-021-06422-1","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T01:02:47Z","timestamp":1635642167000},"page":"471-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exclusion criteria of breast cancer clinical trial protocols: a descriptive analysis"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8468-7625","authenticated-orcid":false,"given":"Clara","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-6110","authenticated-orcid":false,"given":"Nicole E.","family":"Caston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-9785","authenticated-orcid":false,"given":"Gabrielle B.","family":"Rocque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"key":"6422_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/EDBK_243729","volume":"39","author":"RD Nipp","year":"2019","unstructured":"Nipp RD, Hong K, Paskett ED (2019) Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book 39:105\u2013114","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"33","key":"6422_CR2","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA et al (2017) Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol 35(33):3737\u20133744","journal-title":"J Clin Oncol"},{"issue":"36","key":"6422_CR3","doi-asserted-by":"publisher","first-page":"9282","DOI":"10.1200\/JCO.2005.02.6245","volume":"23","author":"PN Lara Jr","year":"2005","unstructured":"Lara PN Jr, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A et al (2005) Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23(36):9282\u20139289","journal-title":"J Clin Oncol"},{"issue":"3","key":"6422_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","volume":"111","author":"JM Unger","year":"2019","unstructured":"Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME (2019) Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. JNCI 111(3):245\u2013255","journal-title":"JNCI"},{"issue":"16","key":"6422_CR5","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1056\/NEJMp1615879","volume":"376","author":"JA Beaver","year":"2017","unstructured":"Beaver JA, Ison G, Pazdur R (2017) Reevaluating eligibility criteria\u2014balancing patient protection and participation in oncology trials. N Engl J Med 376(16):1504\u20131505","journal-title":"N Engl J Med"},{"issue":"22","key":"6422_CR6","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720\u20132726","journal-title":"JAMA"},{"issue":"7","key":"6422_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","volume":"21","author":"JH Lewis","year":"2003","unstructured":"Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383\u20131389","journal-title":"J Clin Oncol"},{"issue":"33","key":"6422_CR8","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","volume":"35","author":"SM Lichtman","year":"2017","unstructured":"Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D et al (2017) Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. J Clin Oncol 35(33):3753\u20133759","journal-title":"J Clin Oncol"},{"issue":"9","key":"6422_CR9","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-20-3868","volume":"27","author":"A Magnuson","year":"2021","unstructured":"Magnuson A, Bruinooge SS, Singh H, Wilner KD, Jalal S, Lichtman SM, Kluetz PG, Lyman GH, Klepin HD, Fleury ME et al (2021) Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clin Cancer Res 27(9):2424\u20132429","journal-title":"Clin Cancer Res"},{"key":"6422_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/EDBK_156686","volume":"35","author":"JM Unger","year":"2016","unstructured":"Unger JM, Cook E, Tai E, Bleyer A (2016) The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 35:185\u2013198","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"6422_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2009.24.3881","volume":"28","author":"MM Hsieh","year":"2010","unstructured":"Hsieh MM, Tisdale JF, Rodgers GP, Young NS, Trimble EL, Little RF (2010) Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol 28(10):1633\u20131637","journal-title":"J Clin Oncol"},{"issue":"22","key":"6422_CR12","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1161\/CIRCULATIONAHA.118.039180","volume":"139","author":"J Bonsu","year":"2019","unstructured":"Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, Wei L, Jneid H, Addison D (2019) Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation 139(22):2594\u20132596","journal-title":"Circulation"},{"issue":"13","key":"6422_CR13","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","volume":"23","author":"CA Townsley","year":"2005","unstructured":"Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23(13):3112\u20133124","journal-title":"J Clin Oncol"},{"key":"6422_CR14","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration. Cancer Clinical Trial Eligibility Criteria: Brain Metastases. https:\/\/www.fda.gov\/media\/121317\/download. Accessed Aug 2021"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06422-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06422-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06422-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T10:33:18Z","timestamp":1642415598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06422-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6422"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06422-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-614366\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-614366\/v2","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"assertion":[{"value":"29 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Rocque received research funding from Genentech, Pfizer, and Carevive and consulting fees for Genentech and Pfizer. The other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent was obtained from all authors included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Alabama at Birmingham Office of the Institutional Review Board for Human Use (IRB-300001910) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}